Managing Drug-Drug Interaction between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil

Abstract : No drug-drug interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA). We here report the case of a hepatitis C virus-infected patient treated with 3D and MPA for vasculitis. In light of the threat of drug-drug interaction, the concentration of MPA was measured before, during, and 15 days after the end of the 3D treatment. Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Document type :
Journal articles
Liste complète des métadonnées

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01614699
Contributor : Laurent Jonchère <>
Submitted on : Wednesday, October 11, 2017 - 11:59:15 AM
Last modification on : Wednesday, May 16, 2018 - 11:23:07 AM

Identifiers

Citation

F. Lemaitre, Z. Ben Ali, C. Tron, C. Jezequel, C. Boglione-Kerrien, et al.. Managing Drug-Drug Interaction between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil. Therapeutic Drug Monitoring, 2017, 39 (4), pp.305-307. 〈10.1097/FTD.0000000000000397〉. 〈hal-01614699〉

Share

Metrics

Record views

55